Ozempic Maker Novo Nordisk Invests Over $1 Billion In New Denmark Production Facility, Closer To Add 3 More From Catalent
Danish pharmaceutical firm Novo Nordisk A/S (NYSE:NVO) announced plans to invest approximately $1.20 billion (8.5 billion Danish kroner) to establish a new production facility in Odense, Denmark. The investment marks the first time in this century that Novo Nordisk breaks ground in Denmark by establishing a new production site.
Novo Nordisk’s takeover of Catalent and the Danish firm’s push to launch a new generation of drugs could boost the importance ...
The Danish Medicines Agency said it would ask European authorities to review two new studies that point to a link between ...
Novo Nordisk's Ozempic will become the first and only GLP-1 drug to be shown to reduce progression of kidney disease in ...
Danish studies have found a potential link between the diabetes drug Ozempic and a rare eye condition called non-arteritic ...
Novo Nordisk said the European Union’s drug regulator supports a label expansion of its Ozempic diabetes drug to reflect its ...
3don MSN
It’s quickly become evident that GLP-1 drugs for diabetes, weight loss, and more are the new wonder drugs—if only people ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback